Women's nephrology · KIMS Secunderabad
Lupus Podocytopathy — Nephrotic Syndrome in Lupus Without Immune Complex Deposits
Lupus podocytopathy is a recently recognised and clinically distinct form of lupus-associated kidney disease — characterised by heavy nephrotic syndrome in a patient with systemic lupus erythematosus (SLE), but with minimal or absent immune complex deposits on kidney biopsy. This distinguishes it from the classical forms of lupus nephritis (Classes I–V, which are all defined by immune complex deposition in the glomeruli). In lupus podocytopathy, the kidney biopsy shows podocyte injury (foot process effacement on electron microscopy) without the immune complex deposits that are the hallmark of classical lupus nephritis — essentially a minimal change disease or FSGS pattern occurring in the context of SLE.
The clinical importance of identifying lupus podocytopathy lies in its treatment: it typically responds dramatically to steroids — mimicking primary minimal change disease — rather than requiring the aggressive immunosuppression (cyclophosphamide, mycophenolate, belimumab) used for classical immune complex-mediated lupus nephritis Classes III and IV. Kidney biopsy with electron microscopy — to confirm the absence of immune complex deposits — is the essential diagnostic test that makes this distinction.
Distinguishing lupus podocytopathy from classical lupus nephritis
| Feature | Lupus Podocytopathy | Classical Lupus Nephritis (Class III/IV/V) |
|---|---|---|
| Mechanism | Podocyte injury without immune complex deposition — cytokine-mediated, similar to primary MCD | Immune complex deposition (mesangial, subendothelial, or subepithelial) — complement activation, glomerular inflammation |
| LM | Minimal change or FSGS pattern — no proliferative changes | Proliferative changes (endocapillary proliferation, wire-loops, crescents in III/IV) or subepithelial deposits (V) |
| IF | Minimal or absent IgG, IgA, IgM, C3, C1q — the 'full house' pattern is absent | 'Full house' pattern — IgG + IgA + IgM + C3 + C4 + C1q — pathognomonic of lupus nephritis |
| EM (key finding) | Diffuse podocyte foot process effacement (above 80%) · No or sparse tubuloreticular inclusions · No immune deposits | Tubuloreticular inclusions in endothelial cells (hallmark of lupus) · Subendothelial, subepithelial, or mesangial immune deposits |
| Clinical | Nephrotic syndrome · eGFR typically preserved · C3 and C4 may be normal | Nephrotic or nephritic-nephrotic syndrome · eGFR often impaired · C3 and C4 typically low |
| Treatment | Rapid complete response to oral prednisolone within 4–8 weeks | Requires combination immunosuppression — prednisolone + cyclophosphamide or mycophenolate ± rituximab or belimumab |
Clinical presentation
Lupus podocytopathy presents in a patient with known or newly diagnosed SLE with:
Sudden onset nephrotic syndrome — heavy proteinuria (above 3.5g/day), hypoalbuminaemia (serum albumin below 25 g/L), and generalised oedema. The severity of nephrotic syndrome may be dramatic — rapidly developing massive oedema within days.
Preserved or mildly impaired eGFR — unlike proliferative lupus nephritis (Class III/IV) where eGFR is often significantly impaired at presentation.
Active SLE serology — positive ANA, elevated anti-dsDNA, with or without other features of active SLE (rash, arthralgia, serositis).
Normal or minimally low complement — unlike proliferative lupus nephritis where C3 and C4 are typically markedly reduced from classical pathway complement consumption.
Diagnosis — kidney biopsy with EM at KIMS
Kidney biopsy is mandatory to distinguish lupus podocytopathy from classical lupus nephritis — the distinction cannot be made on clinical or serological grounds alone. At KIMS:
Light microscopy (LM)
Shows minimal change pattern or FSGS pattern, without the proliferative changes of Class III/IV lupus nephritis.
Immunofluorescence (IF)
Minimal or absent immunoglobulin and complement staining. The absence of the 'full house' pattern (IgG + IgA + IgM + C3 + C4 + C1q) that defines lupus nephritis is the key IF finding.
Electron microscopy (EM)
Diffuse podocyte foot process effacement (above 80% of the glomerular capillary surface). Absence of dense deposits or only sparse mesangial deposits. Tubuloreticular inclusions may be sparse or absent.
Treatment-changing distinction
The combination of minimal IF + diffuse foot process effacement on EM in a patient with SLE confirms lupus podocytopathy — a treatment-changing distinction from Class V lupus nephritis (membranous lupus — which also causes nephrotic syndrome but requires different treatment).
Treatment
Prednisolone — the primary treatment
High-dose oral prednisolone (1 mg/kg/day, maximum 60mg/day) produces complete remission (proteinuria below 300mg/day) in 70 to 80% of lupus podocytopathy patients within 4 to 8 weeks. This rapid, complete steroid response differentiates lupus podocytopathy from classical Class V lupus membranous nephropathy (which responds more slowly and incompletely to steroids alone). Tapering over 6 months after remission — relapse occurs in 30 to 50%, requiring re-treatment.
Hydroxychloroquine
The background treatment for all SLE — reduces lupus disease activity and the frequency of podocytopathy relapses. All SLE patients with nephritis are maintained on hydroxychloroquine unless contraindicated.
Mycophenolate or calcineurin inhibitors for relapsing disease
For patients who relapse on prednisolone reduction — mycophenolate mofetil or tacrolimus are added as steroid-sparing agents. Rituximab for refractory or frequently relapsing cases.
Book a Lupus Nephrology Consultation at KIMS — Women's Nephrology Programme
Frequently Asked Questions — Lupus Podocytopathy
Classical lupus nephritis (WHO/ISN Classes I through V) is caused by immune complex deposition in the glomeruli — antibody-antigen complexes activate complement and cause glomerular inflammation. Lupus podocytopathy is a distinct entity where the podocytes (the specialised cells that maintain the glomerular filtration barrier) are injured by a different mechanism — likely cytokine-mediated — without significant immune complex deposition. The clinical distinction is crucial: classical proliferative lupus nephritis (Class III/IV) requires aggressive immunosuppression to prevent irreversible glomerular scarring, while lupus podocytopathy responds to steroids alone in most cases.
Yes — lupus podocytopathy is essentially a minimal change disease or FSGS pattern occurring in the context of SLE. The podocyte injury and foot process effacement seen on EM in lupus podocytopathy are identical to primary minimal change disease. The distinction from primary MCD is made by the clinical context (the patient has SLE with positive ANA and anti-dsDNA) and by the presence of tubuloreticular inclusions on EM (a hallmark of interferon-driven conditions like SLE) — even if immune complex deposits are absent. Both lupus podocytopathy and primary MCD respond well to steroids, which is why early recognition of lupus podocytopathy prevents inappropriate escalation to cyclophosphamide-level immunosuppression.
Electron microscopy is the only modality that can demonstrate diffuse podocyte foot process effacement and simultaneously confirm the absence of immune complex deposits. On light microscopy, lupus podocytopathy appears as minimal change disease or FSGS — identical to non-lupus causes of these patterns. On immunofluorescence, the absent or minimal staining distinguishes it from classical lupus nephritis. On EM, the combination of foot process effacement (confirming podocyte injury) and absent or sparse deposits (confirming the non-immune-complex mechanism) provides the definitive diagnosis. Without EM, lupus podocytopathy cannot be reliably distinguished from Class V lupus membranous nephropathy or from other nephrotic causes.
Lupus podocytopathy alone — unlike proliferative lupus nephritis — rarely causes progressive kidney failure if adequately treated. The podocyte injury is largely reversible with steroids in most patients. However, FSGS-pattern lupus podocytopathy (where the podocyte injury has progressed to cause focal glomerular scarring) carries a higher risk of progressive CKD — the FSGS lesions represent permanent nephron loss. Long-term outcomes are best when remission is achieved early and maintained with hydroxychloroquine and, where necessary, steroid-sparing agents.
KIMS Secunderabad — Dr. Susmitha Chandragiri (women's nephrology subspecialty), kidney biopsy with full LM + IF + EM panel (EM performed in-house — essential for foot process effacement quantification and deposit absence confirmation), anti-dsDNA and complement monitoring, prednisolone induction with hydroxychloroquine maintenance, mycophenolate and calcineurin inhibitor for relapsing disease, rituximab for refractory cases. NABH and NABL accredited. Call 040-4488-5000.